Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

Kwong Kwok Wong*, Nicholas W. Bateman, Chun Wai Ng, Yvonne T.M. Tsang, Charlotte S. Sun, Joseph Celestino, Tri V. Nguyen, Anais Malpica, R. Tyler Hillman, Jianhua Zhang, P. Andrew Futreal, Christine Rojas, Kelly A. Conrads, Brian L. Hood, Clifton L. Dalgard, Matthew D. Wilkerson, Neil T. Phippen, Thomas P. Conrads, George L. Maxwell, Anil K. SoodDavid M. Gershenson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Low-grade serous ovarian cancer (LGSOC) is a rare disease that occurs more frequently in younger women than those with high-grade disease. The current treatment is suboptimal and a better understanding of the molecular pathogenesis of this disease is required. In this study, we compared the proteogenomic analyses of LGSOCs from short- and long-term survivors (defined as < 40 and > 60 months, respectively). Our goal was to identify novel mutations, proteins, and mRNA transcripts that are dysregulated in LGSOC, particularly in short-term survivors. Methods: Initially, targeted sequencing of 409 cancer-related genes was performed on 22 LGSOC and 6 serous borderline ovarian tumor samples. Subsequently, whole-genome sequencing analysis was performed on 14 LGSOC samples (7 long-term survivors and 7 short-term survivors) with matched normal tissue samples. RNA sequencing (RNA-seq), quantitative proteomics, and phosphoproteomic analyses were also performed. Results: We identified single-nucleotide variants (SNVs) (range: 5688–14,833 per sample), insertion and deletion variants (indels) (range: 880–1065), and regions with copy number variants (CNVs) (range: 62–335) among the 14 LGSOC samples. Among all SNVs and indels, 2637 mutation sites were found in the exonic regions. The allele frequencies of the detected variants were low (median12%). The identified recurrent nonsynonymous missense mutations included KRAS, NRAS, EIF1AX, UBR5, and DNM3 mutations. Mutations in DNM3 and UBR5 have not previously been reported in LGSOC. For the two samples, somatic DNM3 nonsynonymous missense mutations in the exonic region were validated using Sanger sequencing. The third sample contained two missense mutations in the intronic region of DNM3, leading to a frameshift mutation detected in RNA transcripts in the RNA-seq data. Among the 14 LGSOC samples, 7754 proteins and 9733 phosphosites were detected by global proteomic analysis. Some of these proteins and signaling pathways, such as BST1, TBXAS1, MPEG1, HBA1, and phosphorylated ASAP1, are potential therapeutic targets. Conclusions: This is the first study to use whole-genome sequencing to detect somatic mutations in LGSOCs with matched normal tissues. We detected and validated novel mutations in DNM3, which were present in 3 of the 14 samples analyzed. Additionally, we identified novel indels, regions with CNVs, dysregulated mRNA, dysregulated proteins, and phosphosites that are more prevalent in short-term survivors. This integrated proteogenomic analysis can guide research into the pathogenesis and treatment of LGSOC.

Original languageEnglish
Article number606
JournalJournal of Translational Medicine
Issue number1
StatePublished - Dec 2022
Externally publishedYes


  • Global phosphoproteomics
  • Global proteomics
  • Low-grade serous ovarian cancer
  • RNAseq
  • Whole-genome sequencing


Dive into the research topics of 'Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors'. Together they form a unique fingerprint.

Cite this